PitchVault flagged 2 deal-breakers and 3 significant gaps. Four months later, every gap had a concrete answer — and the deck moved from “do not send” to diligenceable.
TAM is presented with zero supporting data — no top-down figure, no bottoms-up logic, no addressable customer count times price. The market sizing section is effectively missing, which is a deal-breaker for any institutional check.
The competitive landscape is entirely absent. Without naming and disqualifying alternatives — electrochromic glass, thermochromic inks, e-ink, traditional coatings — investors have no way to assess whether Color Reality is a feature or a category.
"IP is secured" was stated but not framed as a why-now catalyst. Investors need to understand what changed — and why the window to invest is now rather than in 12 months.
The B2B licensing model was mentioned but the mechanics were unclear. How much does each phase cost? What does a 3-partner, 36-month model look like? Investors cannot build a model from a description.
The IP story mentioned one granted patent without articulating the full defensive stack — manufacturing process, proprietary formula, and trade secrets that block reverse-engineering. The moat was understated.
This was one iteration. Yusuke went from 63 to 72 in a single pass — five targeted changes, no full rewrite. Each additional iteration compounds. The ceiling is higher than 72.
Lower is better. Composite band dropped from MEDIUM 57 to MEDIUM 44 — a 13-point de-risking.
Exit Risk (#12) is weighted 0% at pre-seed — not scored until Series B+. Composite excludes Exit Risk at this stage.
Verdict: Building Foundations — team and traction assembled, one dimension at CRITICAL.
At 63/100 with a missing TAM, no competitive landscape, and prototype-pass traction that was paused, Color Reality was a founder-credibility story — the kind of conviction bet an angel makes on a team and a thesis, not on commercial evidence.
Institutional pre-seed funds required market sizing logic and competitive positioning before committing. Both were absent, making the deck un-diligenceable.
A granted JP patent, PCT positive opinion, a coherent ARM/Dolby licensing model with explicit phase fees, EAP validation at ¥100k/user/month, three re-engaging enterprise partners, and a named three-layer IP moat together make this a diligenceable pre-seed story for institutional investors.
Seed and Series A funds need signed LOIs or commercial contracts. The enterprise POC pipeline is real but unsigned — converting at least one named partner to a paid POC term sheet is the next milestone before approaching later-stage capital.
Convert one named enterprise partner to a signed paid POC term sheet ($300–600k)
Moves from pipeline to contract — the gap between institutional pre-seed and seed readiness. Seed funds require signed LOIs. One deal converts this from a thesis to a traction story.
Externalize proprietary formula and manufacturing process documentation
VaultOps™ Key-Person Risk is at CRITICAL band — the chemical formula, CMY ratios, and UV-blocking formulation exist only in the founder's knowledge. One departure could end the company.
Build EAP retention data — frequency, session counts, and reorder intent for ¥100k/user/month cohort
Traction Validation risk remains HIGH (62/100). Retention curves convert "prototype users" into "indispensable product" evidence — the PMF signal investors need before a Series A conversation.
Add three-partner financial sensitivity model — best/base/worst case through 36 months
The 36-month model is stated. Investors want to stress-test: what if Partner 2 delays 6 months? What if POC converts at $200k instead of $300k? Sensitivity shows you've modelled the downside.
Every red flag above was invisible to Yusuke until PitchVault named it. Get the same four-score, five-lens analysis on your deck — section-by-section breakdown, risk profile, moat assessment, and a ranked action roadmap.